🇺🇸 FDA
Patent

US 10245259

Methods of treating RBP4 related diseases with triazolopyridines

granted A61KA61K31/4545A61K31/4985

Quick answer

US patent 10245259 (Methods of treating RBP4 related diseases with triazolopyridines) held by Belite Bio, Inc expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Belite Bio, Inc
Grant date
Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4545, A61K31/4985, A61K31/519, A61K31/5365